» Articles » PMID: 3940648

Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3

Overview
Journal Cancer Res
Specialty Oncology
Date 1986 Feb 1
PMID 3940648
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Monoclonal antibody B72.3 binds a high-molecular-weight tumor-associated glycoprotein identified as TAG-72. This study reports the partial purification and characterization of TAG-72 from a xenograft of a human carcinoma cell line, LS-174T, which expresses high levels of this antigen. The tumor homogenate was initially fractionated by Sepharose CL-4B chromatography. The high-molecular-weight TAG-72, found in the exclusion volume, was then subjected to two sequential passages through B72.3 antibody affinity columns. At each step of the procedure, TAG-72 content was quantitated using a competition radioimmunoassay, and the degree of purification was expressed as the ratio of antigen in units to total protein. The three-step procedure produced a purification of TAG-72 with minimal contamination by other proteins as shown by polyacrylamide gel electrophoresis, followed by staining with Coomassie Blue or periodic acid/Schiff reagent. The density of affinity-purified TAG-72, as determined by cesium chloride gradient ultracentrifugation, was found to be 1.45 g/ml. This density determination, together with the high molecular weight of TAG-72, its resistance to Chondroitinase digestion, the presence of blood group-related oligosaccharides, and sensitivity to shearing into lower-molecular-weight forms suggest that TAG-72 is a mucin-like molecule.

Citing Articles

A Concept for Preoperative and Intraoperative Molecular Imaging and Detection for Assessing Extent of Disease of Solid Tumors.

Hitchcock C, Chapman G, Mojzisik C, Mueller Jr J, Martin Jr E Oncol Rev. 2024; 18:1409410.

PMID: 39119243 PMC: 11306801. DOI: 10.3389/or.2024.1409410.


Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success.

Rodriguez G, Yakubovich E, Vanderhyden B Cancers (Basel). 2023; 15(23).

PMID: 38067396 PMC: 10705691. DOI: 10.3390/cancers15235694.


Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors.

Matsumoto Y, Ju T Cancers (Basel). 2023; 15(14).

PMID: 37509200 PMC: 10377354. DOI: 10.3390/cancers15143536.


Development of an automated chemiluminescent immunoassay for cancer antigen 72-4 and the evaluation of its analytical performance.

Yanagihara F, Okura H, Ichikawa H, Shirakawa T, Pan Y, Tu B Pract Lab Med. 2023; 34:e00308.

PMID: 36713933 PMC: 9879778. DOI: 10.1016/j.plabm.2023.e00308.


Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.

Hu S, Sun M, Li M, Xue X, Terkeltaub R, Wang C Rheumatology (Oxford). 2022; 62(7):2435-2443.

PMID: 36409036 PMC: 10321093. DOI: 10.1093/rheumatology/keac656.